UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 106

Sortiert nach

Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Journal of clinical oncology, 2009-12, Vol.27 (34), p.5838-5847

2009

Volltextzugriff (PDF)

An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models

Breast cancer research : BCR, 2013-09, Vol.15 (5), p.R85-R85, Article R85

2013

Volltextzugriff (PDF)

A Model of Acquired Autoresistance to a Potent ErbB2 Tyrosine Kinase Inhibitor and a Therapeutic Strategy to Prevent Its Onset in Breast Cancer

Proceedings of the National Academy of Sciences - PNAS, 2006-05, Vol.103 (20), p.7795-7800

2006

Volltextzugriff (PDF)

Acquired Resistance to Small Molecule ErbB2 Tyrosine Kinase Inhibitors

Clinical cancer research, 2008-11, Vol.14 (21), p.6730-6734

2008

Volltextzugriff (PDF)

Medical oncologists' perspectives of the Veterans Affairs National Precision Oncology Program

PloS one, 2020-07, Vol.15 (7), p.e0235861-e0235861

2020

Volltextzugriff (PDF)

Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas

Journal of clinical oncology, 2005-08, Vol.23 (23), p.5305-5313

2005

Volltextzugriff (PDF)

Photo-activated psoralen binds the ErbB2 catalytic kinase domain, blocking ErbB2 signaling and triggering tumor cell apoptosis

PloS one, 2014-02, Vol.9 (2), p.e88983-e88983

2014

Volltextzugriff (PDF)

Phase II Study of Predictive Biomarker Profiles for Response Targeting Human Epidermal Growth Factor Receptor 2 (HER-2) in Advanced Inflammatory Breast Cancer With Lapatinib Monotherapy

Journal of clinical oncology, 2008-03, Vol.26 (7), p.1066-1072

2008

Volltextzugriff (PDF)

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

Oncogene, 2002-09, Vol.21 (41), p.6255-6263

2002

Volltextzugriff (PDF)

Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor

PloS one, 2015-11, Vol.10 (11), p.e0142845-e0142845

2015

Volltextzugriff (PDF)

X-Ray Psoralen Activated Cancer Therapy (X-PACT)

PloS one, 2016-09, Vol.11 (9), p.e0162078-e0162078

2016

Volltextzugriff (PDF)

Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies

Journal of clinical oncology, 2005-04, Vol.23 (11), p.2502-2512

2005

Volltextzugriff (PDF)

A network of substrates of the E3 ubiquitin ligases MDM2 and HUWE1 control apoptosis independently of p53

Science signaling, 2013-05, Vol.6 (274), p.ra32

2013

Volltextzugriff (PDF)

Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells

Proceedings of the National Academy of Sciences - PNAS, 2007-06, Vol.104 (25), p.10607-10612

2007

Volltextzugriff (PDF)

Regulation of survivin by ErbB2 signaling : Therapeutic implications for ErbB2-overexpressing breast cancers

Cancer research (Chicago, Ill.), 2006-02, Vol.66 (3), p.1640-1647

2006

Volltextzugriff (PDF)

Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer

Breast cancer research : BCR, 2012-04, Vol.14 (2), p.R62-R62, Article R62

2012

Volltextzugriff (PDF)

Resistance to ErbB2 tyrosine kinase inhibitors in breast cancer is mediated by calcium-dependent activation of RelA

Molecular cancer therapeutics, 2010-02, Vol.9 (2), p.292-299

2010

Volltextzugriff (PDF)

Visualizing Borrelia burgdorferi Infection Using a Small-Molecule Imaging Probe

Journal of clinical microbiology, 2021-06, Vol.59 (7), p.e0231320-e0231320

2021

Volltextzugriff (PDF)

Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects

Investigational new drugs, 2005-01, Vol.23 (1), p.39-49

2005

Volltextzugriff (PDF)

Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells

Oncogene, 2005-09, Vol.24 (41), p.6213-6221

2005

Volltextzugriff (PDF)

Selective ERBB2 and BCL2 Inhibition Is Synergistic for Mitochondrial-Mediated Apoptosis in MDS and AML Cells

Molecular cancer research, 2021-05, Vol.19 (5), p.886-899

2021

Volltextzugriff (PDF)

Pertuzumab protects the achilles' heel of trastuzumab--emtansine

Clinical cancer research, 2014-01, Vol.20 (2), p.278-280

2014

Volltextzugriff (PDF)

Delivery of a Healthy Baby After First-Trimester Maternal Exposure to Lapatinib

Clinical breast cancer, 2006-10, Vol.7 (4), p.339-341

2006

Volltextzugriff (PDF)

Epidermal Growth Factor and Granulocyte Colony Stimulating Factor Signaling Are Synergistic for Hematopoietic Regeneration

Stem cells (Dayton, Ohio), 2018-02, Vol.36 (2), p.252-264

2018

Volltextzugriff (PDF)

A Fluorescent Hsp90 Probe Demonstrates the Unique Association between Extracellular Hsp90 and Malignancy in Vivo

ACS chemical biology, 2017-04, Vol.12 (4), p.1047-1055

2017

Volltextzugriff (PDF)

1 – 25 von 106

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(102)
Mit Volltextzugriff
(93)

Publikationsform

Artikel
(104)
Reviews
(2)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(74)
Humans
(69)
Life Sciences & Biomedicine
(65)
Female
(36)
Oncology
(31)
Biological And Medical Sciences
(30)
Medical Sciences
(24)
Animals
(22)
Male
(21)
Adult
(19)
Middle Aged
(18)
Tumors
(18)
Cell Line, Tumor
(17)
Breast Neoplasms - Metabolism
(16)
Mice
(15)
Breast Cancer
(14)
Receptor, Erbb-2 - Metabolism
(14)
Apoptosis
(13)
Antineoplastic Agents - Therapeutic Use
(12)
Biochemistry & Molecular Biology
(12)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models

A Model of Acquired Autoresistance to a Potent ErbB2 Tyrosine Kinase Inhibitor and a Therapeutic Strategy to Prevent Its Onset in Breast Cancer

Acquired Resistance to Small Molecule ErbB2 Tyrosine Kinase Inhibitors

Medical oncologists' perspectives of the Veterans Affairs National Precision Oncology Program

Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas

Photo-activated psoralen binds the ErbB2 catalytic kinase domain, blocking ErbB2 signaling and triggering tumor cell apoptosis

Phase II Study of Predictive Biomarker Profiles for Response Targeting Human Epidermal Growth Factor Receptor 2 (HER-2) in Advanced Inflammatory Breast Cancer With Lapatinib Monotherapy

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor

X-Ray Psoralen Activated Cancer Therapy (X-PACT)

Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies

A network of substrates of the E3 ubiquitin ligases MDM2 and HUWE1 control apoptosis independently of p53

Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells

Regulation of survivin by ErbB2 signaling : Therapeutic implications for ErbB2-overexpressing breast cancers

Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer

Resistance to ErbB2 tyrosine kinase inhibitors in breast cancer is mediated by calcium-dependent activation of RelA

Visualizing Borrelia burgdorferi Infection Using a Small-Molecule Imaging Probe

Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects

Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells

Selective ERBB2 and BCL2 Inhibition Is Synergistic for Mitochondrial-Mediated Apoptosis in MDS and AML Cells

Pertuzumab protects the achilles' heel of trastuzumab--emtansine

Delivery of a Healthy Baby After First-Trimester Maternal Exposure to Lapatinib

Epidermal Growth Factor and Granulocyte Colony Stimulating Factor Signaling Are Synergistic for Hematopoietic Regeneration

A Fluorescent Hsp90 Probe Demonstrates the Unique Association between Extracellular Hsp90 and Malignancy in Vivo

Suchergebnisse filtern